CompletedNCT03187769
ALKS 3831 or Olanzapine and Weight in Young Adults With Schizophrenia or Bipolarity
About this title
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Read the official source — NCT03187769Medication studyAges 16–40Multiple countries
Understand this study
Who was this study for?
Listed age limits: 16 years to 40 years.
- Listed locations
- Little Rock and 56 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 8, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 426
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Austria, ...
- Age range
- From 16 Years to 40 Years
- Official registry ID
- NCT03187769
- Official title
Show the full official title
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Rogers, United States · Garden Grove, United States
52 more locations
- San Diego, United States
- Stanford, United States
- Jacksonville, United States
- North Miami, United States
- Atlanta, United States
- Augusta, United States
- Chicago, United States
- Winfield, United States
- Kalamazoo, United States
- Kansas City, United States
- St Louis, United States
- Las Vegas, United States
- Cincinnati, United States
- Eugene, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Richardson, United States
- San Antonio, United States
- Vienna, Austria
- München, Germany
- Galway, Ireland
- Jerusalem, Israel
- Tel HaShomer, Israel
- Brescia, Italy
- Naples, Italy
- Torino, Italy
- Poznan, Poland
- Arkhangelsk, Russia
- Moscow, Russia
- Roshchino, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tonnel'nyy, Russia
- Busan, South Korea
- Daegu, South Korea
- Naju, South Korea
- Seoul, South Korea
- Oviedo, Spain
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Stepanovka, Ukraine
- Guildford, United Kingdom
- Headington, United Kingdom
- London, United Kingdom
- Maidstone, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 3831 and Olanzapine.
Who was this study for?
Listed age limits: 16 years to 40 years.
Want to explore more studies?
Explore studiesRelated studies
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...
Paliperidone and valproic acid levels in psychosis and bipolarity